Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal ...

The therapy showed a ‘favourable’ safety profile both as a single agent and in combination with standard-of-care treatment.

Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced positive topline results from two ...

U.S. News released its list of best diets for 2025: the low-FODMAP diet landed on top for irritable bowel syndrome and the ...

The following is a summary of “Association between the triglyceride-glucose index and liver fibrosis in adults with ...

Among the general US population, simple and affordable non-invasive liver fibrosis scoring systems may be able to identify individuals at risk for HF.

Study Finds Targeting Inflammation May Not Help Reduce Liver Fibrosis in MAFLD July 26, 2024 — Researchers uncovered new information about the role inflammation plays in mitigating liver ...

Patients with indeterminate chronic hepatitis B (CHB) phase are at risk of progressing to advanced liver disease and hepatocellular carcinoma (HCC), according to study results published in the Journal ...

The liver, serving as the body's natural filtration system, faces significant challenges from alcohol consumption. As this ...

The liver can regenerate itself, but there are factors that make self-repair impossible. Find out what they are here.

Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that ...